- CHASE clinical trial progressing; interim review planned for September 2019
- $1,675,000 raised since beginning of Q2 2019
- ZanthoSyn® sell-through strong; top selling antioxidant nationwide at GNC in 2019
- ZanthoSyn® sell-in down in Q2 2019 but has increased in Q3 2019
- ZanthoSyn® retail expansion beyond GNC planned
PR Newswire
HONOLULU, Aug. 14, 2019